15000L RO1-Based Purified Water Purification System for Pharmaceutical Applications

Name: 15000L RO1-Based Purified Water Purification System for Pharmaceutical Applications
Brand: Shandong Eagle Water Treatment Technology Co.,Ltd
SKU: 2235975695

Shandong, ChinaShandong Eagle Water Treatment Technology Co.,Ltd

US$30,000.00-150,000.00

1 Set

Product profile

Application

Biotechnology Industry, Chemical industry, Food & Beverage Factory, Food Safety, Pharmaceutical Industry

Capacity

15000L/H

Certification

CE, FDA, GMP, ISO

Model NO.

250L/H-100000L/H

Control System

Fully Automatic

Treatment Process

Chlorination, Electrodeionization, Filtration, Ozonation, Reverse Osmosis, Softening, Ultrafiltration, UV Disinfection

Warranty of core components

1 Year

Material

SS316L

Machinery Test Report

Provided

Electrical Equipment

Siemens(Germany)

Size

Customized

Processing Type

Reverse Osmosis

Transport Package

Wooden Case

Specification

15000L/H

Trademark

WEMAC

Origin

China

HS Code

8421219990

Production Capacity

50000pieces/Year

Company profile

Shandong Eagle Water Treatment Technology Co.,LtdShandong, China

Business Type: Manufacturer/Factory, Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableAverage Response Time: ≤1.45h

AI-Powered supplier vetting

SummaryThe supplier is identified as a trading company with biomass energy-related technical services in its stated business scope. It reports OEM and ODM capabilities, sample- and design-based customization, four production lines, and 50 quality-control staff. Export-related evidence is mixed: one slice states 41%–50% of sales come from exports and exports through agents and self-operated import/export rights, while another identifies the primary market as domestic and a separate slice states no overseas service locations or overseas agents. Service-management documentation is weak, with no written procedures or records for supplier assessment, corrective actions, or complaint handling. No SDK, no new products in the past year, and only two years of R&D engineer experience are reported. Financial and sustainability evidence is insufficient for a firm assessment, while customer-case evidence indicates validation-document experience and exports to more than 40 countries and regions.

After-Sales capabilityAfter-sales and service-management controls appear weak: there are no written procedures or records for service-capability assessment, corrective and preventive actions, or complaint handling. The supplier also reports no overseas warehouse, showroom, agent, branch, or offline trade-show capability, although it lists acceptable service terms and 13 qualified suppliers; these do not establish effective after-sales support.

R&D capabilityThe supplier reports ODM service and customization from samples and designs, but no available SDK, no new products during the past year, and only two years of total R&D-engineer experience. These explicit limitations outweigh the stated ODM capability for an overall innovation assessment.

Production capacityThe supplier reports four production lines, 50 quality-control staff, and combined facilities including flatting, cutting, and automatic welding machines. However, finished-product inspection has instructions but no written records, so production resources are demonstrated while process-documentation control is incomplete.

Customization capabilityBoth slices explicitly report customization from samples and from designs, and the supplier also states that it provides ODM services. This directly supports a demonstrated ability to handle customized products.

Client casesThe supplier states that its sales volume ranks first in China, that it has exported to more than 40 countries and regions, and that it has provided pharmaceutical validation documents including DQ, IQ, OQ, PQ, FAT, and SAT. These statements provide explicit evidence of broad market reach and sector-relevant customer experience, although no individual customer names are given.